Nexiam (Esomeprazole Magnesium Trihydrate)

The active ingredient irreversibly inhibits the gastric H+/K+ ATPase (proton pump) in parietal cells, which is the final step in acid secretion. By blocking this pump, it markedly reduces gastric acidity, allowing damaged mucosa to heal and relieving symptoms of acid‑related conditions.

The specific dose and dosing schedule of Nexiam are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal acid control while minimizing potential risks.

Safety data for esomeprazole magnesium trihydrate in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the Nexiam product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nexiam’s active ingredient, esomeprazole magnesium trihydrate, is the S‑enantiomer of omeprazole and generally provides more consistent acid suppression than racemic mixtures. Compared with other PPIs, it may achieve faster healing of erosive lesions, though clinical outcomes depend on individual patient factors and adherence.

Nexiam should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nexiam is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but consistent timing each day helps maintain steady acid control. Patients should follow the prescribing clinician’s instructions regarding timing relative to meals.

Serious risks, though rare, include Clostridioides difficile‑associated diarrhea, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, liver enzyme elevations, acute interstitial nephritis, and low magnesium levels with prolonged therapy. Patients should seek immediate medical attention if they experience severe rash, persistent diarrhea, or signs of infection.

Nexiam is contraindicated in patients with known hypersensitivity to esomeprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients taking medications that have a documented major interaction unless the benefits outweigh the risks.